|
1
|
De Weger VA, Beijnen JH and Schellens JH:
Cellular and clinical pharmacology of the taxanes docetaxel and
paclitaxel - A review. Anticancer Drugs. 5:488–494. 2014.
View Article : Google Scholar
|
|
2
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: Invasive Breast Cancer Version 1.2016, NCCN
Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.
14:324–354. 2016.PubMed/NCBI
|
|
3
|
Jones SE, Erban J, Overmoyer B, Budd GT,
Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI,
et al: Randomized phase III study of docetaxel compared with
paclitaxel in metastatic breast cancer. J Clin Oncol. 23:5542–5551.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gradishar WJ, Tjulandin S, Davidson N,
Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III
trial of nanoparticle albumin-bound paclitaxel compared with
polyethylated castor oil-based paclitaxel in women with breast
cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumors. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hayes DF, Thor AD, Dressler LG, Weaver D,
Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle
JN, et al: Cancer and Leukemia Group B (CALGB) Investigators: HER2
and response to paclitaxel in node-positive breast cancer. N Engl J
Med. 357:1496–1506. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hugh J, Hanson J, Cheang MC, Nielsen TO,
Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, et
al: Breast cancer subtypes and response to docetaxel in
node-positive breast cancer: Use of an immunohistochemical
definition in BCIRG 001 trial. J Clin Oncol. 27:1168–1176. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Penault-Llorca F, André F, Sagan C,
Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC,
Bibeau F, Antoine M, et al: Ki67 expression and docetaxel efficacy
in patients with estrogen receptor-positive breast cancer. J Clin
Oncol. 27:2809–2815. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes - dealing with the diversity of breast cancer: Highlights
of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pritchard KI, Shepherd LE, O'Malley FP,
Andrulis IL, Tu D, Bramwell VH and Levine MN: National Cancer
Institute of Canada Clinical Trials Group: HER2 and responsiveness
of breast cancer to adjuvant chemotherapy. N Engl J Med.
354:2103–2111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
An overview of the randomized trials. Lancet. 365:1687–1717. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Swain SM, Jeong JH, Geyer CE Jr,
Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J,
Vogel VG, Erban JK, et al: Longer therapy, iatrogenic amenorrhea
and survival in early breast cancer. N Engl J Med. 362:2053–2065.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alba E, Calvo L, Albanell J, De la Haba
JR, Arcusa Lanza A, Chacon JI, Sanchez-Rovira P, Plazaola A, Lopez
Garcia-Asenjo JA, Bermejo B, et al: GEICAM: Chemotherapy (CT) and
hormonotherapy (HT) as neoadjuvant treatment in luminal breast
cancer patients: Results from the GEICAM/2006-03, a multicenter,
randomized, phase-II study. Ann Oncol. 23:3069–3074. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sakamoto G, Inaji H, Akiyama F, Haga S,
Hiraoka M, Inai K, Iwase T, Kobayashi S, Sakamoto G, Sano M, et al:
Japanese Breast Cancer Society: General rules for clinical and
pathological recording of breast cancer 2005. Breast Cancer.
12(Suppl): S1–S27. 2005.PubMed/NCBI
|
|
15
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: American Society of Clinical Oncology;
College of American Pathologists: Recommendations for human
epidermal growth factor receptor 2 testing in breast cancer:
American Society of Clinical Oncology/College of American
Pathologists clinical practice guideline update. Arch Pathol Lab
Med. 138:241–256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Foulkes WD, Reis-Filho JS and Narod SA:
Tumor size and survival in breast cancer - a reappraisal. Nat Rev
Clin Oncol. 7:348–353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Amir E, Miller N, Geddie W, Freedman O,
Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G,
Laupacis A, et al: Prospective study evaluating the impact of
tissue confirmation of metastatic disease in patients with breast
cancer. J Clin Oncol. 30:587–592. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marty M, Cognetti F, Maraninchi D, Snyder
R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A,
et al: Randomized phase II trial of the efficacy and safety of
trastuzumab combined with docetaxel in patients with human
epidermal growth factor receptor 2-positive metastatic breast
cancer administered as first-line treatment: The M77001 study
group. J Clin Oncol. 23:4265–4274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gabriel N. Hortobagyi: Drug therapy:
Treatment of breast cancer. N Engl J Med. 339:974–984. 1998.
View Article : Google Scholar : PubMed/NCBI
|
